Sjögren's disease & overlap diseases
Iguratimod suppresses Tfh cell differentiation in primary Sjögren’s syndrome patients through inhibiting Akt/mTOR/STAT3 signaling
Authors' conclusion
IGU suppresses Tfh cell differentiation in pSS patients through interacting with PDK1 and suppressing Akt-mTOR-STAT3 signaling.
Study context
- Population
- pSS patients treated with iguratimod (IGU) for 3 months; healthy controls (in vitro)
- Participants
- 13 pSS patients
Methodological detailsprospective
- Prospective
Main finding
As reported in the abstract
- Tfh, plasmablast and plasma cells suppressed by IGU treatment at 1 and 3 months
- Tfh cell differentiation and function significantly inhibited by IGU in pSS patients and healthy controls in vitro
- PDK1 identified as a target of IGU during Tfh cell differentiation; downstream Akt phosphorylation attenuated by IGU
- mTORC1 activity and STAT3 phosphorylation suppressed by IGU, with downregulation of BCL6 and upregulation of PRDM1
- Akt activator restored IGU-suppressed Tfh cell differentiation
Original publication
Iguratimod suppresses Tfh cell differentiation in primary Sjögren’s syndrome patients through inhibiting Akt/mTOR/STAT3 signaling. Arthritis Res Ther. Published 22 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →